Volume 10, Number 10—October 2004
Dispatch
Mycobacterium triplex Pulmonary Disease in Immunocompetent Host
Table 1
Clinical and microbiological features of pulmonary infection with Mycobacterium triplexa
Characteristic | Patient described in reference 15 | Patient described in reference 16 | Our patient |
---|---|---|---|
Age/Sex | 67/F | 54/F | 54/F |
Symptoms | Hemoptysis | Cough, hemoptysis, fever, fatigue | Cough, fatigue |
Findings | Bronchiectases, lung nodules | Lung infiltrates and nodule (0.3 cm) | Bronchiectases, lung nodules, cavitations |
Collected samples (no.) | Bronchial aspirate (1), sputum (3) | BAL (2), sputum (4) | Bronchial aspirate (7), BAL (2) |
Smear-positive | None | None | 6 |
Culture-positive | 3 | 3 | 9 |
Mean no. CFU/mL (range) | NR | NR | 693 (144–2,772) |
In vitro testing | |||
S | RMP, SM, CLA | NR | CLA |
I | CIP | NR | AN, CIP, EMB, ETH, RBT, SM |
R | EMB, INH, PZA | NR | INH, RMP |
Therapeutic schedule (mo.) | RMP, CIP, EMB, CLA (18) | RMP, INH, CLA (NR) | INH, RMP, EMB (6); EMB, CLA (9); LVX, CLA, EMB (9) |
Outcome | Healed | NR | Slight improvement |
aBAL, bronchoalveolar lavage; NR, not reported; S, susceptible; I, moderately susceptible; R, resistant; RMP, rifampin; SM, streptomycin; CLA, clarithromycin; CIP, ciprofloxacin; AN, amikacin; EMB, ethambutol; ETH, ethionamide; RBT, rifabutin; INH, isoniazid; PZA, pyrazinamide; LVX, levofloxacin.
References
- Primm TP, Lucero CA, Falkinham JO III. Health impacts of environmental mycobacteria. Clin Microbiol Rev. 2004;17:98–106. DOIPubMedGoogle Scholar
- Falkinham JO III. Mycobacterial aerosols and respiratory disease. Emerg Infect Dis. 2003;9:763–7.PubMedGoogle Scholar
- American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med. 1997;156:S1–25.PubMedGoogle Scholar
- Floyd MM, Guthertz LS, Silcox VA, Duffey PS, Jang I, Desmond EP, Characterization of an SAV organism and proposal of Mycobacterium triplex sp. nov. J Clin Microbiol. 1996;34:2963–7.PubMedGoogle Scholar
- Selvarangan R, Whei-Kuo W, Trang TN, Carlson LDC, Wallis CK, Stiglich SK, Characterization of a novel group of mycobacteria and proposal of Mycobacterium sherrisii sp. nov. J Clin Microbiol. 2004;42:52–9. DOIPubMedGoogle Scholar
- Springer B, Whei-Kuo W, Bodmer T, Haase G, Pfyffer GE, Kroppenstedt RM, Isolation and characterization of a unique group of slowly growing mycobacteria: description of Mycobacterium lentiflavum sp. nov. J Clin Microbiol. 1996;34:1100–7.PubMedGoogle Scholar
- Cingolani A, Sanguinetti M, Antinori A, Larocca LM, Ardito F, Posteraro B, Disseminated mycobacteriosis caused by drug-resistant Mycobacterium tripex in a human immunodeficiency virus–infected patient during highly active antiretroviral therapy. Clin Infect Dis. 2000;31:177–9. DOIPubMedGoogle Scholar
- Hoff E, Sholtis M, Procop G, Sabella C, Goldfarb J, Willie R, Mycobacterium tripex infection in a liver transplant patient. J Clin Microbiol. 2001;39:2033–4. DOIPubMedGoogle Scholar
- Zeller V, Nardi AL, Truffot-Pernot C, Sougakoff V, Stankoff B, Katlama C, Disseminated infection with a mycobacterium related to Mycobacterium tripex with central nervous system involvement associated with AIDS. J Clin Microbiol. 2003;41:2785–7. DOIPubMedGoogle Scholar
- Metchock B, Nolte FS, Wallace RJ Jr. Mycobacterium. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, editors. Manual of clinical microbiology. 7th ed. Washington: ASM Press; 1999. p. 399–437.
- Tortoli E, Mariottini A, Mazzarelli G. Evaluation of INNO-LiPA MYCOBACTERIA v2: improved reverse hybridization multiple DNA probe assay for mycobacterial identification. J Clin Microbiol. 2003;41:4418–20. DOIPubMedGoogle Scholar
- Tortoli E, Bartoloni A. Burrini, Mantella A, Simonetti MT. Utility of high performance liquid chromatography for identification of mycobacterial species rarely encountered in clinical laboratories. Eur J Clin Microbiol Infect Dis. 1995;14:240–3. DOIPubMedGoogle Scholar
- Harmsen D, Rothganger J, Singer C, Albert J, Frosch M. Intuitive hypertext-based molecular identification of microorganisms. Lancet. 1999;353:291. DOIPubMedGoogle Scholar
- Siddiqi SH, Heifets LB, Cynamon MH, Hooper NM, Laszlo A, Libonati JP, Rapid broth macrodilution method for determination of MICs for Mycobacterium avium isolates. J Clin Microbiol. 1993;31:2332–8.PubMedGoogle Scholar
- National Committee for Clinical Laboratory Standards. Susceptibility testing of mycobacteria, nocardia, and other aerobic actinomycetes. Approved standard M24-A. Wayne (PA): the Committee; 2003.
- Heifets L. Dilemmas and realities in drug susceptibility testing of Mycobacterium avium-Mycobacterium intracellulare and other slowly growing nontuberculous mycobacteria. In: Heifets LB, editor. Drug susceptibility in the chemotherapy of mycobacterial infections. Boca Raton (FL): CRC Press; 1991. p. 123–46.
- Suomalainen S, Koukila-Kähkölä P, Brander E, Katila ML, Pilonen A, Paulin L, Pulmonary infection by an unusual slowly growing nontuberculous mycobacterium. J Clin Microbiol. 2001;39:2668–71. DOIPubMedGoogle Scholar
- McMullan R, Xu J, Kelly M, Stanley T, Moore JE, Millar BC, Mycobacterium triplex pulmonary infection in an immunocompetent patient. J Infect. 2002;44:263–4. DOIPubMedGoogle Scholar
Page created: April 11, 2011
Page updated: April 11, 2011
Page reviewed: April 11, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.